Understanding the impact of COVID-19 on lung health
The UK Interstitial Lung Disease Long-COVID19 Study (UKILD-Long COVID): Understanding the Burden of Interstitial Lung Disease in Long COVID.
Imperial College London · NCT05514522
This study is testing how COVID-19 affects lung health in people with ongoing breathing problems to better understand their condition and improve future treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Imperial College London (other) |
| Locations | 1 site (London) |
| Trial ID | NCT05514522 on ClinicalTrials.gov |
What this trial studies
This observational study aims to recruit 2000 individuals who have experienced COVID-19 and are experiencing persistent respiratory symptoms. Participants will undergo cross-sectional imaging to assess the extent of interstitial lung disease (PC-ILD) and its natural history. The study will explore risk factors, biomarkers, and the long-term implications of SARS-CoV-2 infection, with the goal of informing treatment strategies and clinical trial stratification. It will run for 18 months and is managed by the Imperial College National Heart and Lung Institute.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 who have had confirmed SARS-CoV-2 infection and are experiencing persistent respiratory symptoms.
Not a fit: Patients with significant pre-existing lung disease or life-limiting illnesses may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and management of lung complications following COVID-19.
How similar studies have performed: Other studies have shown success in understanding post-COVID conditions, but this specific focus on PC-ILD is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age \>18 years old -99 years old 2. Evidence of SARS-CoV-2 infection confirmed by PCR or serology 3 months (+/- 6 weeks) earlier 3. Clinical indication for a chest CT scan as per clinician judgment Exclusion Criteria: 1. Life-limiting illness within 12 months 2. Significant pre-existing lung disease prior to March 2020, which in the investigator's judgement could make the chest CT scans difficult to interpret
Where this trial is running
London
- Imperial College Healthcare trust — London, United Kingdom (RECRUITING)
Study contacts
- Principal investigator: Gisl Jenkins — Imperial College London
- Study coordinator: mark weeks, Dr
- Email: m.weeks@imperial.ac.uk
- Phone: +44 (0)20 7594 7972
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Interstitial Lung Disease, SARS-CoV-2 Infection, COVID, PC-ILD population